That there is a trial ongoing in China came as a surprise to many, who didn't know that researchers there had overcome one of the field's biggest challenges — the need to produce large numbers of iPs-cell-derived cardiomyocytes that are pure enough to be used in people. This takes a lot of time and effort to get right, so very few companies or research groups have successfully done it.
Help Cell-foundry ensures the safety and consistency of producing transplanted cells. The Ophthalmology Department of Jiangsu Province Hospital also has a superior basic and clinical platform for ophthalmology. Our cooperation will promote translational research, and its strategic value and social benefits are considerable.
My goal is to assess the safety and efficacy of cell injection, and it was very encouraging when my patients get better after surgery. Tumor could be a main concern when we talk about cell therapy, but we have not encountered one yet. Meanwhile, our cell injection did not cause sustained dysfunction in heart rhvthm.
It is of great clinical value to develop safe, effective cell products without ethical concerns as early as possible. Help Thera-X holds the technology in iPSC, while Jiangsu Province Hospital has rich clinical experience. Together we can bring cell therapy from the bench to the bedside.
Myocardial regeneration is a hot research field, and iPSC-derived cardiac cells hold the promise for patients who suffer from heart failure and eager for heart transplantation. I'm glad to see projects using iPSC-derived cardiomyocytes to treat heart failure got launched in China, and I sincerely hope these projects go well.
Heart failure is an unconquered battlefield that burdens families and our society heavily. For the treatment of end-stage heart failure, there is no truly effective treatment except heart transplantation. But most of the patients died waiting for the surgery; that's why exploring more effective treatment modalities is so urgent. Help Thera-X is the first company in China to use iPSC for cell therapy and has accumulated rich clinical experience in treating heart failure. I hope Help Thera-X will provide professional cell therapy services for millions of heart failure patients in China soon.
Help Thera-X-University of Macau Joint Lab is a collaborative R&D lab founded by Help-Thera X and Zhuhai UM Science & Technology Research Institute (ZUMRI). The joint lab locates in the Traditional Chinese Medicine Science and Technology Industrial Park of Co-operation between Guangdong and Macao in Hengqin. The joint lab is operated by members from Help-Thera X and Prof. Guokai CHEN (Assistant Dean, Faculty of Health Sciences, UM), together with staff from ZUMRI.
This joint lab aims to deepen the collaboration among industry, academia and research institutes, accelerate technology transfer of research achievements in stem cell biology and clinical application, and promote the development of related industries through joint R&D projects and exchange programs.
The Oujiang Laboratory was officially inaugurated by Zhejiang government and is located in the core area of the National Independent Innovation Demonstration Zone - ZheNan Science and Technology City. The lab focused on regeneration regulation and eye & brain health, the construction principle is "focusing on the frontier, domestically and globally".
Help-Thera X-Oujiang Joint Lab aims to break through vital technical and scientific issues and explore new biomaterials and biotechnology in treating cardiovascular diseases using stem cell technology.